Gland Pharma Limited (NSE:GLAND)
India · Delayed Price · Currency is INR | Market Cap | 499.22B +60.1% |
| Revenue (ttm) | 67.25B +17.6% |
| Net Income | 11.29B +46.5% |
| EPS | 68.41 +46.3% |
| Shares Out | 164.97M |
| PE Ratio | 44.23 |
| Forward PE | 38.34 |
| Dividend | 20.00 (0.68%) |
| Ex-Dividend Date | Aug 11, 2026 |
| Volume | 1,560,855 |
| Open | 2,959.30 |
| Previous Close | 2,959.30 |
| Day's Range | 2,938.60 - 3,033.90 |
| 52-Week Range | 1,573.60 - 3,042.00 |
| Beta | 0.59 |
| Analysts | Buy |
| Price Target | 2,856.07 (-5.62%) |
| Earnings Date | Nov 6, 2026 |
About Gland Pharma
Gland Pharma Limited engages in manufacturing and sale of injectable formulations in India, the United States, Europe, Canada, Australia, New Zealand, and internationally. It engages in research and development of active pharmaceutical ingredient products, including synthesis of complex drug molecules, such as low molecular weight heparins, corticosteroids, peptides, and cytotoxic molecules. The company also offers its products for various therapeutic categories, such as anti- diabetic, anti-malarial, anti-infectives, anti-neoplastic, and neuro... [Read more]
Financial Performance
In fiscal year 2026, Gland Pharma's revenue was 64.31 billion, an increase of 14.50% compared to the previous year's 56.17 billion. Earnings were 10.27 billion, an increase of 47.07%.
Financial StatementsAnalyst Summary
According to 14 analysts, the average rating for GLAND stock is "Buy." The 12-month stock price target is ₹2,856, which is a decrease of -5.62% from the latest price.
News
Gland Pharma Transcript: Q1 26/27
Q1 FY 2027 saw 20% revenue growth, 28% adjusted EBITDA margin, and 47% PAT growth, driven by strong CDMO and B2B performance, new launches, and operational efficiency. Strategic agreements and capacity expansions position the company for 15–20% CAGR over the next four years.
Gland Pharma Quarterly report: Q1 2027
Gland Pharma has published its Q1 2027 quarterly earnings report on August 10, 2026.
Gland Pharma Slides: Q1 2027
Gland Pharma has posted slides in relation to its Q1 2027 quarterly earnings report, which was published on August 10, 2026.
India's Gland Pharma beats quarterly profit view on strong Europe, US sales
India's Gland Pharma reported a bigger-than-expected first-quarter profit on Monday, boosted by strong sales in its key European and U.S. markets.
Earnings To Watch: Gland Pharma Ltd (NSE:GLAND) Q1 2027 -- GF Value Sees 5% Downside
Earnings To Watch: Gland Pharma Ltd (NSE:GLAND) Q1 2027 -- GF Value Sees 5% Downside
Gland Pharma, Neuland enter into long-term sterile API CDMO partnership
Gland Pharma and Neuland Labs form long-term sterile API CDMO partnership; new cGMP/FDA/EU suite at Visakhapatnam JNPC adds ~1,400 kg/year capacity.
Top stocks to buy : Stock market recommendations for today - check list
Stock market recommendations: Honasa Consumer, Gland Pharma, Bata India, and Siemens - these are the top stocks to buy picked by Somil Mehta, Head of Retail Research, Mirae Asset ShareKhan for August ...
Customs slaps Rs 7 cr tax, penalty on Gland Pharma
Pharma Co To Appeal Order; Customs Raises ₹3.53cr IGST Demand
Top gainers today: cohance at ₹457.80 surges 12.97%, piramal pharma at ₹168.89 up 6.55%, gland pharma at ₹2,298.20 gains 5.10%
In a session marked by declines in the broader market, with the Sensex down 1.16% at 76,200.68 and the Nifty 50 also dropping 1.16% to 23,824.10, several stocks have defied…
Gland Pharma announces resignation of independent director Satyanarayana Murthy Chavali
Gland Pharma has announced the resignation of its independent director, Mr. Satyanarayana Murthy Chavali, as per a regulatory filing with the National Stock Exchange of India (NSE). The announcement f...
Divi's Labs jumps 3.33%, Piramal Pharma 3.77%, Gland Pharma 2.68% after Pentagon blacklists WuXi AppTec
Shares of Indian pharmaceutical and CDMO companies surged sharply on June 9, 2026, after the US Pentagon designated WuXi AppTec as a Chinese military company, triggering a broad re-rating of…
Gland Pharma increases share capital with allotment of 2,03,259 equity shares
Gland Pharma has announced the allotment of 2,03,259 equity shares to 77 employees under its Employee Stock Options Scheme 2025. This move, approved by the ESOP Compensation Committee of the…
Top gainers today: gland pharma at ₹2,156.60 up 15.43%, coforge at ₹1,348.10 up 5.15%, persistent systems at ₹4,944.10 up 5.15%
In today's trading session, the Indian stock market displayed a modest upward trend, with the Sensex rising by 0.10% to 75,315.04 and the Nifty 50 inching up by 0.03% to…
Top gainers in morning trade: gland pharma at ₹2,127 up 13.85%, shipping corporation of India at ₹348.50 up 5.16%, carborundum universal at ₹1,139 up 3.32%
In the morning session, the Indian stock market displayed mixed sentiments as the SENSEX dipped to 74,789.97, marking a 0.60% decline, while the NIFTY 50 fell by 0.62% to 23,496.40.…
Why Gland Pharma shares are up over 12% today? Explained
Shares of Gland Pharma surged more than 12% in early trade on Monday after the company reported a strong set of Q4FY26 earnings, driven by robust growth in revenue, profitability,…
Gland Pharma Transcript: Q4 25/26
Q4 FY 2026 delivered record revenue and profitability, led by strong CDMO growth, new launches, and Cenexi turnaround. FY 2027 guidance is 12%-13% revenue growth (constant currency), with CDMO and new products as key drivers. GLP-1 upside is excluded from guidance.
Gland Pharma Quarterly report: Q4 2026
Gland Pharma has published its Q4 2026 quarterly earnings report on May 15, 2026.
Gland Pharma Slides: Q4 2026
Gland Pharma has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on May 15, 2026.
Gland Pharma Annual report: Q4 2026
Gland Pharma has published its Q4 2026 annual report on May 15, 2026.
Gland Pharma reports audited financial results for year ending March 2026
Gland Pharma has announced its audited financial results for the quarter and financial year ending 31 March 2026. The results, which include both standalone and consolidated figures, have been reviewe...
Gland Pharma reports 97% growth in Q4 FY26 profit after tax
Gland Pharma, an injectable-focused pharmaceutical company, has announced its financial results for the fourth quarter and year ending 31 March 2026, showcasing significant growth in revenue and profi...
Gland Pharma Q4 Results: Net profit jumps 96% YoY to Rs 366.68 crore, revenue up 22%
Gland Pharma reported a strong performance for the quarter ended March 2026, with sharp growth in revenue and profitability on a year-on-year basis. The pharmaceutical company posted consolidated reve...
Top Q4 results today, May 15: Tata Steel, NHPC, Power Grid, Cochin Shipyard, Gland Pharma among key companies to announce earnings
Several listed companies are scheduled to announce their financial results for the quarter and financial year ended March 2026 on Friday, May 15, 2026. Major earnings to watch include announcements…
What To Expect From Gland Pharma Ltd (NSE:GLAND) Q4 2026 Earnings
What To Expect From Gland Pharma Ltd (NSE:GLAND) Q4 2026 Earnings
Gland Pharma to consider stock options grant under ESOP 2025 scheme
Gland Pharma has announced that its ESOP Compensation Committee will convene on Friday, May 15, 2026, to discuss and potentially approve the grant of stock options under the Gland Pharma…